Colleen Hopkins

Colleen Hopkins advises life sciences clients on the policy impacts of health reform on their commercial and advocacy priorities.

She focuses on state implementation of the Affordable Care Act’s health insurance exchanges, part D policy, and payment, and on assisting pharmaceutical companies with changing policy landscapes.

Prior to joining Avalere, Colleen was a senior associate at Community Anti-Drug Coalitions of America, where she identified and interpreted novel research for use in evidence-based strategies related to tobacco prevention policies, cancer screenings, and geographic health disparities. Prior to that, she worked as a research assistant for Information Innovators, Inc., where she conducted qualitative and quantitative research on telehealth systems in rural communities.

Colleen has an MPH from George Mason University and a BS in biology from the University of Mary Washington.

Authored Content

As policymakers discuss ways to curb program expenditures and improve patient affordability in Medicare Part D, the role of charitable assistance in helping beneficiaries with out-of-pocket (OOP) costs has garnered interest. To understand the relationship between charitable assistance and various Part D metrics, Avalere examined Part D prescription drug claims for beneficiaries without the Low Income Subsidy (LIS) for 2014 and 2018.

The CalPERS Basic Plan Drug List, which is the formulary for all California public employees, includes 222 brand drugs and 287 generic drugs. In contrast, drug coverage in the Veterans Administration (VA) and Medi-Cal (California's Medicaid program) is far more limited than the CalPERS drug list.